News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Dr. Michael Quirmbach has succeeded Dr. Riku Rautsola as CEO and president. Rautsola will transition to the role of a senior advisor to the executive leadership team.
Quirmbach has been with CordenPharma since 2014 as the chief business officer. Prior to this, he held several positions in the industry at companies including Siegfried, Dr. Reddy’s, and Solvias.
“In my new role as CEO and president, I plan to continue the growth of CordenPharma as a trusted, reliable and highly-respected CDMO by focusing on our Integrated supply chain solution, supported with a clear, profitable growth strategy defined by our technology platforms,” said Quirmbach.
“Operational excellence, transparent, and effective cost management and customer centricity will determine the foundation of our performance, while accelerated growth and sustained profit remain our ongoing objectives,” he told us. “I look forward to this challenge and anticipate a promising future for CordenPharma in the years to come.”